The efficacy of chNKG2D T cell therapy is demonstrated by an increase in the number of NK cells and activated host CD8+ T cells within the tumor microenvironment, coupled with a marked decrease in the number of Foxp3+ regulatory T cells at the tumor site, which play a key role in tumor-induced immune suppression. This evidence concerns the gene CD8A and neoplasm.